Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | HPGD | P15428 | 3/20 | 0.77 |
| ▸ | RECQL | P46063 | 3/20 | 0.77 |
| ▸ | PKLR | P30613 | 3/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.77 |
| ▸ | CA12 | O43570 | 3/20 | 0.77 |
| ▸ | CA9 | Q16790 | 3/20 | 0.77 |
| ▸ | GALNT2 | Q10471 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | APEX1 | P27695 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | CA1 | P00915 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ellagic Acid SCHEMBL4429252 | 0.90 | KDM4E (0.77) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL20876917 | 0.88 | HPGD (0.79) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL1645767 | 0.88 | KDM4E (1.00) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL30475160 | 0.88 | KDM4E (1.00) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL29439360 | 0.88 | KDM4E (1.00) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL20429 | 0.88 | KDM4E (1.00) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL9792365 | 0.87 | KDM4E (0.72) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL8686551 | 0.86 | KDM4E (0.96) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL2639621 | 0.86 | KDM4E (0.96) | KDM4EMAPTHPGDRECQLPKLR | |
| Ellagic Acid SCHEMBL21590140 | 0.86 | KDM4E (0.96) | KDM4EMAPTHPGDRECQLPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114557905-A | Endogenous cell regulation system and application thereof | 云南美颜美龄生物科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-20110177140-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-07-21 | — | — | US | claimed |
| CN-101835449-A | Use of 4-amidinobenzylamines for cosmetic and/or dermatological use | DSM IP ASSETS BV | 2010-09-15 | — | — | CN | claimed |
| EP-2197409-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | DSM IP Assets B.V. (NL) | 2010-06-23 | — | — | EP | claimed |
| WO-2009026949-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2009-03-05 | — | — | WO | claimed |
| CN-114557905-B | Endogenous cell regulation system and application thereof | 昆明美颜美龄生物科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-114557905-A | Endogenous cell regulation system and application thereof | 云南美颜美龄生物科技有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20130224131-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-20110177140-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-07-21 | — | — | US | disclosed |
| EP-2197409-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | DSM IP Assets B.V. (NL) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009026949-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177140-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | CUTA, PADI4, HNMT | KDM4E 1323/4885MAPT 3287/4885HPGD 638/4885 |
| US-20130224131-A1 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE | CUTA, PADI4, HNMT | KDM4E 1323/4885MAPT 3287/4885HPGD 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.